Zalicus Granted Composition-of-Matter Patent for Z944
Key Patent Provides Broad Coverage for Z944 through April 2029
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 20, 2013--
Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from
pain, today announced that it has been granted a patent by the U.S.
Patent and Trademark office (USPTO) covering its product candidate Z944.
United States patent number 8,377,968 entitled “N-Piperidinyl Acetamide
Derivatives as Calcium Channel Blockers” provides broad coverage for
Z944 including compositions of matter and certain therapeutic methods of
use through April 2029. Z944 is a novel, oral, T-type calcium channel
blocker which has demonstrated efficacy in a number of preclinical
inflammatory pain models and other disease models. Z944 completed Phase
1 single and multiple ascending dose clinical studies in late 2012 and
the Company plans to continue further clinical development with Z944
“This key patent provides the foundation of a solid and enforceable
intellectual property estate for Z944, with issued claims through April
2029,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus.
“Based on our preclinical and early-stage clinical work, we are excited
to further explore the potential of Z944 as a novel, oral, non-opioid
Zalicus Inc. (Nasdaq Global Market: ZLCS) is a biopharmaceutical company
that discovers and develops novel treatments for patients suffering from
pain. Zalicus has a portfolio of proprietary clinical-stage product
candidates targeting pain such as Z160 and Z944 and has entered into
multiple revenue-generating collaborations with large pharmaceutical
companies relating to other products, product candidates and drug
discovery technologies. Zalicus applies its expertise in the discovery
and development of selective ion channel modulators and its combination
high throughput screening capabilities to discover innovative
therapeutics for itself and its collaborators in the areas of pain,
inflammation, oncology and infectious disease. To learn more about
Zalicus, please visit www.zalicus.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning Zalicus, its product candidates, their potential, and its
plans for clinical development. These forward-looking statements about
future expectations, plans, objectives and prospects of Zalicus and its
product candidates may be identified by words like "believe," "expect,"
"may," "will," "should," "seek," “plan” or “could” and similar
expressions and involve significant risks, uncertainties and
assumptions, including risks related to the clinical development of its
product candidates, the unproven nature of the Zalicus Ion channel drug
discovery technology, and those other risks that can be found in the
"Risk Factors" section of Zalicus' annual report on Form 10-K on file
with the Securities and Exchange Commission and the other reports that
Zalicus periodically files with the Securities and Exchange Commission.
Actual results may differ materially from those Zalicus contemplated by
these forward-looking statements. These forward-looking statements
reflect management’s current views and Zalicus does not undertake to
update any of these forward-looking statements to reflect a change in
its views or events or circumstances that occur after the date of this
release except as required by law.